Fusion Pharmaceuticals ROCE 2024

Fusion Pharmaceuticals Aktienanalyse

What does Fusion Pharmaceuticals do?

Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative cancer therapies. The company was founded in Canada in 2014 and has since pursued a unique approach to cancer treatment: targeted radiation therapy. Fusion Pharmaceuticals' business model is based on providing cancer patients with an effective and gentle alternative to conventional treatment methods. The company utilizes a novel technology that allows radioisotopes to be specifically targeted to cancer cells. This enables radiation to be applied directly to the affected areas without damaging healthy tissue. Fusion Pharmaceuticals specializes in the development of therapies for solid tumors. The company collaborates with various partners to offer a wide range of treatment options. The key products currently include: - FP-1001: This product is currently in Phase 1 clinical trials and is intended for the treatment of patients with solid tumors. FP-1001 combines a specific antibody molecule with the radioactive isotope Actinium-225 to selectively destroy cancer cells. - FP-2000: This product is currently in the preclinical phase and aims to provide an effective treatment for pancreatic cancer. FP-2000 combines a specific antibody molecule with the radioactive isotope Lutetium-177 and has the potential to improve the survival rate of patients with this severe disease. - FP-3000: This product is also in the preclinical phase and is intended for the treatment of prostate cancer. FP-3000 combines a specific antibody molecule with the radioactive isotope Copper-67 and has the potential to offer an effective alternative to conventional treatments such as chemotherapy. Fusion Pharmaceuticals has rapidly gained importance in recent years and has attracted numerous prestigious investors. These include Canadian investment firm OrbiMed Advisors LLC and renowned US biotechnology company Johnson & Johnson. The company has also received several awards, including the Innovation Award from the Canadian government in 2019. For the future, Fusion Pharmaceuticals plans to further expand its development pipeline and create new therapies for a wide range of cancer diseases. The company aims to provide cancer patients worldwide with new hope and an effective alternative to conventional treatment methods. Fusion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Fusion Pharmaceuticals's Return on Capital Employed (ROCE)

Fusion Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Fusion Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Fusion Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Fusion Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Fusion Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of Fusion Pharmaceuticals this year?

The ROCE of Fusion Pharmaceuticals is -0.45 undefined this year.

How has the ROCE (Return on Capital Employed) of Fusion Pharmaceuticals developed compared to the previous year?

The ROCE of Fusion Pharmaceuticals has increased by -17.77% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Fusion Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Fusion Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Fusion Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Fusion Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Fusion Pharmaceuticals impact the company?

An increase in the ROCE of Fusion Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Fusion Pharmaceuticals affect the company?

A decrease in ROCE of Fusion Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Fusion Pharmaceuticals?

Some factors that can affect Fusion Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Fusion Pharmaceuticals so important for investors?

The ROCE of Fusion Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Fusion Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Fusion Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Fusion Pharmaceuticals pay?

Over the past 12 months, Fusion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharmaceuticals?

The current dividend yield of Fusion Pharmaceuticals is .

When does Fusion Pharmaceuticals pay dividends?

Fusion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharmaceuticals?

Fusion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharmaceuticals located?

Fusion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharmaceuticals from 5/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Fusion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Fusion Pharmaceuticals in the year 2023?

In the year 2023, Fusion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Fusion Pharmaceuticals pay out the dividend?

The dividends of Fusion Pharmaceuticals are distributed in USD.